IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
SEK 11.25
(0.0%)
SEK 11.25
(0.0%)
| Breakdown | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -164.89 Million | -142.61 Million | 128.64 Million | -89.21 Million | -91.2 Million | -70.79 Million |
| Net Income | -177.83 Million | -113.11 Million | 52.57 Million | -91.45 Million | -95.84 Million | -73.89 Million |
| Depreciation & Amortization | 4.31 Million | 3.98 Million | 3.47 Million | 2.25 Million | 2.93 Million | 1.33 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 8.62 Million | -33.98 Million | 34.29 Million | 183 Thousand | 1.95 Million | 1.97 Million |
| Other non-cash items | 5000.00 | 501 Thousand | 38.29 Million | -195 Thousand | -244 Thousand | -202 Thousand |
| Investing Cash Flow | -293 Thousand | -3.37 Million | -708 Thousand | -394 Thousand | -137 Thousand | -1.05 Million |
| Investments in PPE | -293 Thousand | -3.37 Million | -708 Thousand | -394 Thousand | -137 Thousand | -1.05 Million |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | -500 Thousand | - | - | - | - |
| Financing Cash Flow | 23.68 Million | -3.13 Million | -3.04 Million | 256.09 Million | 67.42 Million | 131.57 Million |
| Debt repayment | -23.68 Million | -3.13 Million | -2.86 Million | -1.61 Million | -1.54 Million | - |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | -180 Thousand | - | - | - |
| Common Stock Issuance | 2.77 Million | - | -180 Thousand | 275.49 Million | 68.97 Million | 131.57 Million |
| Other Financing Activities | 20.9 Million | -3.13 Million | -180 Thousand | -17.78 Million | -1.54 Million | 131.57 Million |
| Accounts receivables | 3.61 Million | 3.63 Million | -12.81 Million | 2.62 Million | -3.77 Million | -2.6 Million |
| Accounts payables | 5 Million | -37.61 Million | 47.1 Million | -2.43 Million | 5.73 Million | 4.57 Million |
| Inventory | -5 Million | 37.61 Million | -47.1 Million | 2.43 Million | -5.73 Million | - |
| Other working capital | 5 Million | -37.61 Million | 47.1 Million | -2.43 Million | 5.73 Million | 4.57 Million |
| Cash at beginning of period | 252.77 Million | 401.89 Million | 277 Million | 110.52 Million | 134.44 Million | 74.7 Million |
| Cash at end of period | 111.3 Million | 252.77 Million | 401.89 Million | 277 Million | 110.52 Million | 134.44 Million |
| Capital Expenditure | -293 Thousand | -3.37 Million | -708 Thousand | -394 Thousand | -137 Thousand | -1.05 Million |
| Effect of forex changes on cash | 35 Thousand | 1000.00 | - | -1000.00 | - | - |
| Net cash flow / Change in cash | -141.46 Million | -149.12 Million | 124.88 Million | 166.48 Million | -23.91 Million | 59.73 Million |
| Free Cash Flow | -165.18 Million | -145.98 Million | 127.93 Million | -89.6 Million | -91.33 Million | -71.84 Million |
| Breakdown | 2024 Q3 | 2024 Q2 | 2024 Q1 | 2023 Q4 | 2023 FY | 2023 Q3 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | - | - | - | - | - | - |
| Net Income | -31.65 Million | -7.05 Million | -39.01 Million | -34.98 Million | -177.83 Million | -40.73 Million |
| Depreciation & Amortization | 1.15 Million | 1.15 Million | 1.15 Million | 1.07 Million | 4.31 Million | 1.08 Million |
| Deferred income taxes | - | - | - | - | - | - |
| Stock-based compensation | - | - | - | - | - | - |
| Change in working capital | 25.62 Million | 6.01 Million | -344 Thousand | 8000.00 | 8.62 Million | 618 Thousand |
| Other non-cash items | 1000.00 | -3.71 Million | 2.64 Million | 2.13 Million | 5000.00 | 2.34 Million |
| Investing Cash Flow | -199 Thousand | - | - | - | -293 Thousand | - |
| Investments in PPE | -199 Thousand | - | - | - | -293 Thousand | - |
| Acquisitions | - | - | - | - | - | - |
| Investment purchases | - | - | - | - | - | - |
| Sales/Maturities of investments | - | - | - | - | - | - |
| Other Investing Activities | - | - | - | - | - | - |
| Financing Cash Flow | -2.81 Million | 25.02 Million | 42 Thousand | 26.36 Million | 23.68 Million | -904 Thousand |
| Debt repayment | -1.96 Million | -25.98 Million | -983 Thousand | -5.45 Million | -23.68 Million | -904 Thousand |
| Dividends payments | - | - | - | - | - | - |
| Common Stock Repurchased | - | - | - | - | - | - |
| Common Stock Issuance | - | - | - | 2.77 Million | 2.77 Million | - |
| Other Financing Activities | -845 Thousand | -957 Thousand | -941 Thousand | 27.28 Million | 20.9 Million | -904 Thousand |
| Accounts receivables | 55.74 Million | -54.02 Million | 2.06 Million | 3.89 Million | 3.61 Million | 4.39 Million |
| Accounts payables | -30.11 Million | 60.03 Million | -2.41 Million | -3.88 Million | 5 Million | -3.77 Million |
| Inventory | - | - | - | 3.88 Million | -5 Million | - |
| Other working capital | - | 60.03 Million | -2.41 Million | -3.88 Million | 5 Million | 1000.00 |
| Cash at beginning of period | 98.27 Million | 73.14 Million | 111.3 Million | 118.81 Million | 252.77 Million | 156.41 Million |
| Cash at end of period | 90.38 Million | 98.27 Million | 73.14 Million | 111.3 Million | 111.3 Million | 118.81 Million |
| Capital Expenditure | -199 Thousand | - | - | - | -293 Thousand | - |
| Effect of forex changes on cash | - | - | - | - | 35 Thousand | - |
| Net cash flow / Change in cash | -7.88 Million | 25.13 Million | -38.16 Million | -7.5 Million | -141.46 Million | -37.59 Million |
| Free Cash Flow | -5.07 Million | 106 Thousand | -38.21 Million | -33.9 Million | -165.18 Million | -36.69 Million |
CDNAF
9852
LAHAV
CRI
TSPOR
AHL-PD